What is Neoleukin Therapeutics, Inc. (NLTX)?

Neoleukin Therapeutics, Inc. (NLTX) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of NLTX?

The current price of NLTX is $3.49. Prices are updated in real time on Stocks360.

What is NLTX's price-to-earnings (PE) ratio?

NLTX's trailing twelve-month PE ratio is -4.42, based on current price and earnings per share data available on Stocks360.

What is NLTX's market capitalization?

NLTX's market capitalization is $8,199,685.00, placing it in the small-cap tier.

Neoleukin Therapeutics, Inc. (NLTX)

Stock analysis · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

$3.49

Market Cap

$8.20M

PE (TTM)

-4.42

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.10

Day Range

$3.42 – $3.59

52-wk Range

$3.42 – $18.80

Avg Volume

N/A

Volume

109.09K

Neoleukin Therapeutics, Inc. (NLTX) is a publicly traded company in the Healthcare sector. Latest price: $3.49. Market cap $8.20M. Trailing PE -4.42. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Nov 14, 2023

EPS $-0.41 vs est. $-0.80

Beat by $0.39

Proprietary Signals

Signal snapshot temporarily unavailable.

About Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology. The company's leading investigational therapy is NL-201, a novel protein meticulously crafted to emulate the therapeutic effects of the IL-2/IL-15 cytokines. This product candidate is intended for the management of various malignancies, including renal cell carcinoma and melanoma. The organization, founded in 2003, was previously known as Aquinox Pharmaceuticals, Inc. before officially changing its name to Neoleukin Therapeutics, Inc. in August 2019. Its operations are based out of Seattle, Washington.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-4.42×
P/S (TTM)	0.00×
P/B	0.36×
PEG	0.02×
P/FCF (TTM)	-0.09×
EV / EBITDA	1.74×
EV / Sales	0.00×
Earnings Yield	-141.17%
Free Cash Flow Yield	-1069.64%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$95.94M
Net Income (TTM)	-$11.58M
Free Cash Flow (TTM)	-$87.71M
Net Debt	-$104.14M
Working Capital	$207.41M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-45.11%
Return on Invested Capital	-53.72%